Analytical Data
-
基因名
FGFR-3
- Application
-
别名
CD333; ACH; CEK2; JTK7; Achondroplasia; Thanatophoric Dwarfism
-
种属
Human
-
表达系统
Yeast
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P22607
-
表达区间
397-806aa
-
蛋白长度
Partial
-
分子量
47.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast Growth Factor Receptor 3 (FGFR3) is a critical receptor involved in various developmental processes, particularly in bone growth and differentiation. Mutations in the FGFR3 gene are associated with several skeletal disorders, including achondroplasia and hypochondroplasia, which lead to disproportionate short stature. In cancer research, aberrant FGFR3 signaling has been implicated in the progression of certain tumors, notably bladder cancer and multiple myeloma, making FGFR3 a potential therapeutic target. Recombinant FGFR3 proteins have become increasingly important for understanding the receptor's biological functions, interactions with ligands, and its role in disease mechanisms. The production of these recombinant proteins facilitates the study of FGFR3's structure-function relationships, helps to identify small molecules or antibodies that can modulate its activity, and supports the development of novel therapeutic strategies aimed at treating FGFR3-related disorders. Advances in molecular cloning and expression systems have enabled researchers to produce high-purity FGFR3 proteins, allowing for detailed functional assays and structural analyses. Such studies are essential not only for elucidating the pathways regulated by FGFR3 but also for the design of targeted drugs that can effectively inhibit or activate this receptor, thereby offering hope for improved treatment options for patients with FGFR3-associated conditions.












